Metastatic castrate-resistant prostate cancer (MCRPC)
Clinical trials for Metastatic castrate-resistant prostate cancer (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new Metastatic castrate-resistant prostate cancer (MCRPC) trials appear
Sign up with your email to follow new studies for Metastatic castrate-resistant prostate cancer (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to outsmart advanced prostate cancer
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will …
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could custom doses of prostate cancer radiation be safer and stronger?
Disease control Recruiting nowThis study tests whether giving a personalized dose of the drug 177Lu-PSMA-617 (Pluvicto) based on kidney function is safer and allows higher doses than the standard fixed dose. Sixty men with metastatic castration-resistant prostate cancer will receive either personalized or fix…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase 1 • Sponsor: Jean-Mathieu Beauregard • Aim: Disease control
Last updated Jun 26, 2026 14:37 UTC